Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Pathfinder Cell Therapy Inc Com USD0.001

Sell:$0.0014 Buy:$0.0014 Change: $0.0001 (7.69%)
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
Sell:$0.0014
Buy:$0.0014
Change: $0.0001 (7.69%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
Sell:$0.0014
Buy:$0.0014
Change: $0.0001 (7.69%)
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pathfinder Cell Therapy, Inc. is a regenerative medicine company. The Company is seeking to develop cell-based and related therapies for the treatment of a range of diseases and medical conditions characterized by organ-specific cell damage. The Company is engaged in developing cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction and other diseases characterized by organ-specific cell damage. The Company has discovered a mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (PCs) themselves being incorporated into the new tissue. PCs have shown efficacy in approximately three different animal models of diabetes, cardiac ischemia and renal reperfusion injury. The Company has tested these models for PCs from both rat and human sources. As of September 30, 2015, the Company had no revenue generated.

Contact details

Address:
12 Bow St
CAMBRIDGE
02138-5104
United States
Telephone:
+1 (617) 2450289
Website:
www.pathfindercelltherapy.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
n/a
ISIN:
US70319A1060
Market cap:
$867,310
Shares in issue:
667.16 million
Sector:
Biotechnology
Exchange:
OTC Bulletin Board
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joerg Gruber
    Chairman of the Board
  • Richard Franklin
    President, Chief Executive Officer, Secretary, Director
  • John Benson
    Chief Financial Officer, Treasurer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.